Document Detail

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
MedLine Citation:
PMID:  8388318     Owner:  NLM     Status:  MEDLINE    
The cytotoxicity of a novel platinum(IV) complex, bis-acetato-amminedichloro-cyclohexylamine platinum(IV) (JM216), has been evaluated in vitro against a panel of human tumor cell lines (predominantly ovarian) representative of models of intrinsic and acquired to cisplatin. In addition, the activity of JM216 administered by the p.o. route has been determined in vivo using the murine ADJ/PC6 plasmacytoma and four human ovarian carcinoma xenograft lines. In vitro, against seven human ovarian carcinoma cell lines, JM216 showed similar cytotoxicity and pattern of cytotoxicity to cisplatin (mean 50% inhibitory concentrations of 3.5 microM for cisplatin and 1.7 microM for JM216). The cytotoxicity of JM216 was more dependent on the time of drug exposure than that of cisplatin, suggesting that extended split-dosing rather than a single bolus administration might be a more appropriate schedule in patients. Using six pairs of acquired cisplatin-resistant and parent human tumor cell lines (four ovarian, one testicular, and one cervical) JM216 exhibited non-cross-resistance (resistance factor of < 1.5) in three whereas tetraplatin exhibited partial or full cross-resistance in all six pairs. Notably, in two of the acquired cisplatin-resistant lines (41McisR and HX/155cisR) where JM216 retained activity, resistance has previously shown to be due primarily to reduced platinum uptake. In vivo, following p.o. administration using the cisplatin-sensitive murine ADJ/PC6 plasmacytoma, JM216 showed antitumor selectivity far superior to that observed for either cisplatin, carboplatin, or tetraplatin. Across four human ovarian carcinoma xenografts of widely differing sensitivity to cisplatin and carboplatin, JM216 exhibited p.o. activity, broadly comparable to that observed for i.v. administered cisplatin and carboplatin and markedly superior to i.p. administered tetraplatin. These antitumor properties suggest that JM216 provides a structural lead to platinum complexes which may circumvent transport-determined acquired resistance to cisplatin and is a suitable candidate as an p.o. administrable platinum complex for phase I clinical trial.
L R Kelland; G Abel; M J McKeage; M Jones; P M Goddard; M Valenti; B A Murrer; K R Harrap
Related Documents :
11874068 - A ten-year remission maintained by 6,272 mg (3,920 mg/m2) cumulative dose of cisplatin-...
21450438 - Appropriate liver resection type for patients with the american joint committee on canc...
2671288 - Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovaria...
8388318 - Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinu...
9703008 - Sickle cell anemia with systemic lupus erythematosus: response to hydroxyurea therapy.
9641218 - Five-year survival in patients with endometrioid carcinoma of the ovary versus those wi...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer research     Volume:  53     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1993 Jun 
Date Detail:
Created Date:  1993-06-21     Completed Date:  1993-06-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2581-6     Citation Subset:  IM    
Drug Development Section, Institute of Cancer Research, Belmont, Sutton, Surrey, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carboplatin / pharmacology
Cisplatin / pharmacology
Drug Resistance
Drug Screening Assays, Antitumor
Leukemia L1210 / drug therapy
Neoplasms / drug therapy*
Neoplasms, Germ Cell and Embryonal / drug therapy
Organoplatinum Compounds / administration & dosage,  pharmacology*
Ovarian Neoplasms / drug therapy
Plasmacytoma / drug therapy
Testicular Neoplasms / drug therapy
Time Factors
Transplantation, Heterologous
Tumor Cells, Cultured
Uterine Cervical Neoplasms / drug therapy
Reg. No./Substance:
0/Organoplatinum Compounds; 129580-63-8/satraplatin; 15663-27-1/Cisplatin; 41575-94-4/Carboplatin; 62816-98-2/tetraplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of...
Next Document:  Laminin regulates a tumor cell chemotaxis receptor through the laminin-binding integrin subunit alph...